Abstract | OBJECTIVE: METHODS: Patients with pathological or cytological diagnosis of NSCLC, measurable lesions, and no prior therapy were enrolled. We administered weekly infusions of 80 mg/m(2) paclitaxel 3 times in a 4-week cycle. In the absence of progressive disease or intolerable toxicity, we treated each patient for a minimum of four cycles. RESULTS: Of 35 patients enrolled, 17 patients achieved partial response, although no complete responses were observed (response rate 49%; 95% confidence interval 32-66%). The median survival time was 55 weeks (range 6-93 weeks). Grade 3 or 4 leukopenia occurred in only 1 patient (3%). Neurotoxicity was the most frequent adverse effect (grades 1 and 2, 26 and 3%, respectively). Serious toxicity, observed in 2 patients (6%), was interstitial pneumonia, and 1 patient died from sequela. CONCLUSION: Low-dose weekly paclitaxel is a promising therapy for advanced NSCLC with high effectiveness and low toxicity.
|
Authors | Kazuhito Yasuda, Tadashi Igishi, Yuji Kawasaki, Mitsunobu Yamamoto, Kazuhiro Kato, Shingo Matsumoto, Masahiro Kotani, Takanori Sako, Yasushi Shigeoka, Akinori Sugitani, Yutaka Histuda, Eiji Shimizu |
Journal | Oncology
(Oncology)
Vol. 65
Issue 3
Pg. 224-8
( 2003)
ISSN: 0030-2414 [Print] Switzerland |
PMID | 14657596
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Copyright | Copyright 2003 S. Karger AG, Basel |
Chemical References |
- Antineoplastic Agents, Phytogenic
- Paclitaxel
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Carcinoma, Squamous Cell
(drug therapy)
- Disease-Free Survival
- Female
- Humans
- Infusions, Intravenous
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Paclitaxel
(administration & dosage, adverse effects)
- Survival Rate
- Treatment Outcome
|